drugset / Trial / NCT02894645

Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study

NCT02894645

Phase 4 Unknown 500 enrolled National University Hospital, Singapore
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The overall objective of this study is to continue to improve the cure rate of childhood acute lymphoblastic leukemia (ALL) in Singapore and Malaysia in the context of a multi-centre cooperative trial using a risk-stratified therapy based primarily on early response to therapy utilizing a simplified minimal residual disease (MRD-lite) platform.

Timeline

Start
2008-10
Primary completion
2018-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified Intravenous
Subject Cytarabine Small molecule Intravenous
Subject Daunorubicin Small molecule Intravenous
Subject Dexamethasone Small molecule Oral
Subject Doxorubicin Other / unclassified Intravenous
Subject Fludarabine Small molecule Intravenous
Subject Imatinib Small molecule Oral
Subject MERCAPTOPURINE ANHYDROUS Small molecule Oral
Subject Methotrexate Small molecule Intrathecal
Subject Prednisolone Other / unclassified Oral
Subject Thioguanine Small molecule Oral
Subject Vincristine Small molecule Intravenous
Subject asparaginase Protein / enzyme biologic Intramuscular